We found that the conflicting activation of mitogenic ERK signaling under conditions of cell cycle arrest induces cytotoxicity in heterogenous AML cell lines following combined treatment with ATRA and CDK4/6i palbociclib. The gene discussed is CDK4; the disease is acute myeloid leukemia.